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PEER-REVIEWED STUDIES IDENTIFYING
PROBLEMS IN THE DESIGN AND
IMPLEMENTATION OF LETHAL
INJECTION FOR EXECUTION
Teresa A. Zimmers, Ph.D.* & Leonidas G. Koniaris, M.D.**
ABSTRACT
Lethal injection was designed and carried out without any re-
search at all. There is no evidence that any literature searches,
animal modeling, clinical studies, or investigations of veterinary
practice were performed prior to the first lethal injection execu-
tion. The paucity of objective information on drug action and
mechanism of death in lethal injection belies the assurance of ex-
pert testimony in lethal injection litigation. Here we review two
peer-reviewed studies on lethal injection for execution in which we
present evidence that lethal injection does not affect death through
the mechanisms intended, that thiopental may be insufficient to as-
sure anesthesia, and that death might be affected through
pancuronium-induced asphyxiation. We conclude that failures in
protocol design and implementation indicate that the conventional
view of lethal injection as an invariably painless death is flawed.
I. EXECUTION BY LETHAL INJECTION
Lethal injection for execution has largely replaced other modali-
ties for the implementation of the death penalty in the United
States. Public repugnance and legal challenges to execution by cya-
* Dr. Zimmers earned her undergraduate degree in Biology from the Massachu-
setts Institute of Technology and her doctorate in Molecular Biology and Genetics at
the Johns Hopkins University School of Medicine. Dr. Zimmers researches mecha-
nisms of tissue growth control in the Departments of Surgery and Cell Biology &
Anatomy at the University of Miami. She is funded by the American Cancer Society
funding for the study of muscle wasting in cancer. She is the author of 5 peer-re-
viewed publications on lethal injection for execution.
** Dr. Koniaris earned his undergraduate degree in Mathematics from the Uni-
versity of Massachusetts Amherst, and his medical doctorate from the Johns Hopkins
University School of Medicine where he completed residency and fellowship training
in surgery. At the University of Miami Miller School of Medicine, Dr. Koniaris spe-
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tion for execution.
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nide gas and electrocution led to the development of lethal injec-
tion as an ostensibly more humane method of judicial killing.'
Lethal injection as the mode of execution has been imposed in 929
of the 1099 executions in the United States from the re-establish-
ment of the death penalty in 1976 to March 8, 2008.2 Lethal injec-
tion involves the administration of three chemicals into the
condemned inmate: thiopental sodium, a barbiturate anesthetic;
pancuronium bromide, an agent that causes muscle paralysis in-
cluding respiratory arrest; and potassium chloride, a depolarizing
agent intended to stop cardiac activity. Modifications of the
United States' lethal injection protocols have also been adopted
world-wide.'
The design of a pharmacologically-based method to impose exe-
cution in the United States has generally been attributed to a de-
sire to find a less expensive and more humane method than
electrocution.4 Some have also contended that the protocol pro-
vides the appearance of a quiet, peaceful death, not dissimilar from
falling asleep. If lethal injection indeed reliably assured a painless
death, the method might comport with some judicial opinions mea-
suring execution methods against "evolving standards of decency
that mark the progress of a maturing society," and prohibiting pun-
ishments that involve "the unnecessary and wanton infliction of
pain," "torture or a lingering death," or which do not accord with
"the dignity of man."5 Other justices and legal scholars have ques-
tioned and even objected to the lethal injection protocol's resem-
blance to a medical procedure with anesthesia, arguing that such an
effort to minimize pain and to cloak execution in the garb of
medicine reduces the retribution aspect of execution and confuses
the public.6
1. See Deborah W. Denno, When Legislatures Delegate Death: The Troubling
Paradox Behind State Uses of Electrocution and Lethal Injection and What It Says
About Us, 63 OHIO ST. L.J. 63 (2002); Deborah W. Denno, The Lethal Injection
Quandary: How Medicine Has Dismantled the Death Penalty, 76 Ford. L. Rev. 49, 105
(2007).
2. DEATH PENALTY INFO. CTR., EXECUTION DATABASE (2008), http://www.
deathpenaltyinfo.org/getexecdata.php.
3. See AMNESTY INTERNATIONAL, EXECUTION By LETHAL INJECTION: A QUAR-
TER CENTURY OF STATE KILLING tbl.1 (2007), http://www.amnesty.org/en/library/as-
set/ACT50/007/2007/en/UTfOVh4UIUJ.
4. See Leonard G. Koniaris et al., Can Lethal Injection For Execution Really Be
"Fixed"?, 369 LANCET 353 (2007).
5. See Beardslee v. Woodford, 395 F.3d 1064, 1070 (9th Cir. 2005).
6. See Jonathan I. Groner, Lethal Injection: A Stain on the Face of Medicine, 325
BMJ:1026-28 (2002).
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Although lethal injection gives the appearance of a medical pro-
cedure, no research whatsoever-clinical, veterinary, medical liter-
ature search, or other-was ever performed prior to the crafting of
the initial Oklahoma legislation or the first lethal injection in
Texas. 7 The designer of the protocol, Jay Chapman, then an
Oklahoma medical examiner, was guided by his experiences as a
patient. He intended each of the drugs to be lethal individually
and that the combination would provide redundancy. Dr. Stanley
Deutsch, then chairman of anesthesiology at an Oklahoma Univer-
sity Medical School arrived at a similar design.9 Each proposed the
combination of an ultra-short acting barbiturate and a paralytic;
potassium chloride was not written into the statute but was added
later.
The use of pancuronium bromide in the lethal injection protocol
most often results in rapid paralysis of the inmate, rendering him
motionless in death. The appearance of restful sleep, however,
would mask extreme pain and suffering if the inmate were aware.
If the thiopental were inadequate to assure anesthesia, then the
inmate would suffer the sensations of paralysis and suffocation in-
duced by the pancuronium and intense burning and cardiac arrest
induced by the potassium chloride. Such pain and suffering may
well violate the Eighth Amendment prohibition against "cruel and
unusual punishment." This is no mere hypothetical consideration;
rather eyewitness testimony, evidence presented in litigation, along
with data and interpretation published in scientific journals indi-
cate there are significant problems with lethal injection, both in
terms of the methodology by which it is imposed as well as the drug
design. This Article discusses peer-reviewed manuscripts in the sci-
entific literature examining the lethal injection protocol.
II. SCIENTIFIC PEER-REVIEW
Peer-review, the process of subjecting an author's work to criti-
cism and evaluation of other experts in the same field, plays a cen-
tral role in what research is published. Journal editors screen
submitted manuscripts for quality and interest by subjecting them
to the criticism and evaluation of other experts in the same field to
ensure that manuscripts meet appropriate research, statistical,
scholarship, and journal criteria. When manuscripts undergo peer-
7. See Koniaris et al., supra note 4, at 352-53.
8. See Jamie Fellner & Sarah Tofte, So Long as They Die: Lethal Injection in the
United States, HUMAN RIGHTS WATCH, April 2006, at 15.
9. See id. at 14.
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review, authors receive rigorous, detailed professional critiques
from the reviewers either anonymously or openly, and are required
to respond to the criticism by performing additional experiments,
re-evaluating data, highlighting weaknesses, and/or incorporating
other citations or interpretations into manuscript. Editors and re-
viewers then together decide whether the data in the revised manu-
script supports the authors' interpretations and whether the results
are of sufficient interest to merit publication. Publication in peer-
reviewed journals provides other investigators the necessary infor-
mation to repeat, reanalyze, and build upon prior data and in that
manner grow the knowledge base in the field. In the absence of
peer-review, data and claims are viewed skeptically by other scien-
tists and experts, particularly when the data and claims are long-
standing and no effort has been made to subject them to peer
review.
In lethal injection litigation, federal and state courts have relied
extensively upon testimony from paid expert witnesses. 10 Such wit-
nesses typically testify on behalf of the inmate or the jurisdiction.
The validity of the testimony rests upon the stated credentials of
the witness and the factual content of the testimony is reviewed
and checked only by the opposing side and its experts. In contrast
to peer-review in the scientific literature, data and claims presented
as expert testimony are not subject to unbiased expert review and
criticism, and thus otherwise scientifically unsupportable conclu-
sions can be used as a basis for judicial opinions. Because the ex-
perts testifying on either side have participated in litigation in
many states, such illegitimate conclusions and conflicting assertions
have been propagated across the United States. In the face of
these incompatible expert opinions, justices themselves have
looked to the scientific literature, most prominently with Supreme
Court Justice Steven Breyer inquiring during oral arguments in
Baze v. Rees1 about the papers discussed here. 12
10. See Teresa A. Zimmers & David A. Lubarsky, Physician Participation in Le-
thal Injection Executions, 20 CURRENT OPINION ANAESTHESIOLOGY 147, 147-51
(2007).
11. Baze v. Rees, 217 S.W.3d 207 (Ky. 2006), cert. granted, 128 S. Ct. 34 (2007).
12. Transcript of Oral Argument, Baze v. Rees, No. 07-5439 (U.S. argued Jan. 7,
2008), available at http://www.oyez.org/cases/2000-2009/2007/2007_07_5439/argument/.
At issue in this case is how judges should evaluate claims that the particular combina-
tion of drugs used to bring about death in Kentucky lethal injection executions causes
suffering that amounts to cruel and unusual punishment, in violation of the Eighth
Amendment.
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At present, there is a paucity of scientific literature on lethal in-
jection for execution. In extensive reviews of the medical litera-
ture, we were unable to find pertinent animal or clinical studies
and unlike animal euthanasics, the lethal injection protocol is not
approved by the Food and Drug Administration. The lethal injec-
tion drugs are administered using doses and methods that are sub-
stantially different from current clinical use and no practicing
anesthesiologist has practical experience using these drugs in situa-
tions similar to executions. The very paucity of scientific informa-
tion about lethal injection raises questions about its acceptability as
a mode of execution and the assurance with which proponents as-
sert its humaneness. We sought to examine all available data per-
taining to lethal injection drug delivery and outcomes and
submitted our findings for peer-review and publication in two of
the world's leading journals in general medicine. Here we summa-
rize those findings.
A. "Inadequate Anesthesia in Lethal Injection for Executions"
in Lancet 2005
In 2005 our group published an integrated examination of the
process of lethal injection. 13 This article, "Inadequate anesthesia in
lethal injection for execution" was published in the second most-
cited general medical journal in the world, the Lancet. The manu-
script underwent a total of three rounds of peer review by multiple
experts in several disciplines. Data presented and analyzed in that
article were derived from freedom of information requests, open
records requests, court testimony, interviews, and the public re-
cord. The major findings of the manuscript were: (1) in many juris-
dictions the execution personnel received no anesthesia or medical
training; (2) drugs were administered remotely; (3) there was no
monitoring for depth of anesthesia; (4) there was no review of out-
comes; and (5) the protocol design contradicted veterinary prac-
tice. 14 The totality of these findings led the authors to the overall
conclusion that the process of lethal injection was flawed both in
the design of the protocol as well as in its implementation.1 5 De-
spite the superficial resemblance to a medical procedure and use of
intravenous tubing and drugs, the lethal injection protocol lacks
the defining hallmarks of medical practice, among them a solid
13. See Leonidas G. Koniaris et al., Inadequate Anaesthesia in Lethal Injection for
Execution, 365 LANCET 1412-14 (2005).
14. See id.
15. See id. at 1414.
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foundation in animal and clinical research and use, expertise of the
practitioner, direct monitoring of physiological signs, documenta-
tion of monitoring and outcomes, responsibility, review, and over-
sight by other experts.
Finally, in the absence of documentation of depth of anesthesia,
we reported the only available objective measure: serum levels of
the anesthetic component, thiopental, measured in blood samples
taken after death from inmates executed by lethal injection and
documented in autopsy reports from Arizona, South Carolina,
North Carolina, and Georgia. We observed that the serum thio-
pental levels in many instances were much lower than that which
would be required for general anesthesia in life. Furthermore, in
some executed inmates, trace or undetectable amounts of thiopen-
tal were observed. We noted that "extrapolation of antemortem
depth of anaesthesia from post-mortem blood thiopental concen-
trations is admittedly problematic."16  Nevertheless, the data
clearly did not support a conclusion that inmates invariably re-
ceived an excess of thiopental. Furthermore, the extraordinary va-
riability of thiopental levels across executions was consistent with
the concerns regarding protocol design, credentials, and techniques
employed.
B. Letters to the Editor of the Lancet
Two letters to the editor critiqued our use of post-mortem thio-
pental levels as a means to extrapolate adequacy of anesthesia in
life. 7 One of these letters was from one of the original reviewers,
who retracted his support for its publication. 18 (This was the
source of Justice Breyer's mistaken conclusion that the paper had
been repudiated.) All the claims made in the other letter, includ-
ing claims that data points were "retracted,"'19 that re-plotting of
data would reveal a time-dependent decline,20 and that an ongoing
study in Oklahoma demonstrated conclusively that thiopental
levels declined after death2' were refuted definitively in a point-by-
16. See id.
17. See Jonathan I. Groner, Response, Inadequate Anaesthesia in Lethal Injection
for Execution, 366 LANCET 1073 (2005); Mark J. Heath et al., Response, Inadequate
Anaesthesia in Lethal Injection for Execution, 366 LANCET 1073-74 (2005).
18. See Groner, supra note 17, at 1073.
19. See Heath et al., supra note 17, at 1073.
20. See id. at 1074.
21. See id.
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point, peer-reviewed response by the original authors.22 Indeed,
although additional thiopental data from Oklahoma autopsies of
executed inmates failed to show a time-dependent decline, they did
confirm that many inmates had thiopental levels below that which
would be required for surgical anesthesia in life.
Taken together, the correspondence and the authors' reply illu-
minated the void of scientific knowledge surrounding the distribu-
tion of thiopental in lethal injection and its potential redistribution
after death. Simply put, there exists no controlled study examining
thiopental post-mortem redistribution. A single case report
demonstrated that post-mortem thiopental levels in one patient ac-
tually increased from levels in life.23 In this manner, as well as in
its high post-mortem cardiac/peripheral venous drug ratio, thiopen-
tal resembles many other drugs that distribute rapidly from blood
into tissues during life, then re-distribute from tissues to blood af-
ter death.24 This suggests that post-mortem serum thiopental levels
might actually under-estimate levels in life.25 While the post-
mortem serum thiopental levels are an imperfect surrogate for
levels in life, the unexpectedly low levels are consistent with other
evidence that the anesthetic component may be inadequate, includ-
ing eyewitness reports of movement and apparent awareness,
26
along with evidence presented in the PLoS Medicine article as dis-
cussed below. In the absence of monitoring and documentation of
depth of anesthesia, however, post-mortem thiopental levels re-
main virtually the only objective available evidence by which to
evaluate the protocol.
In summary, the Lancet study and the authors' response on le-
thal injection demonstrated that significant design and implemen-
tation issues exist in the lethal injection process. To date, the
Lancet paper has withstood three years of scrutiny in the scientific
literature without having a single claim disproved or even substan-
tively challenged. Moreover, the Lancet published several editori-
22. Teresa A. Zimmers et al., Author's Reply, Inadequate Anaesthesia in Lethal
Injection for Execution, 366 LANCET 1074-76 (2005).
23. See William A. Watson et al., Blood Pentobarbital Concentrations During
Thiopental Therapy, 20 DRUG INTELLIGENCE & CLINICAL PHARMACY 283-86 (1986).
24. See Derrick J. Pounder, The Nightmare of Postmortem Drug Changes, in LE-
GAL MEDICINE 163-191 (C. H. Wecht ed. 1993); Helen Russo & Francoise Bressolee,
Pharmacodynamics and Pharmacokinetics of Thiopental, 35 CLINICAL
PHARMACOKINETICS 95-132 (1998).
25. See Groner, supra note 17, at 1074-76; Heath et al., supra note 17, at 1073-74.
26. See Fellner & Tofte, supra note 8, at 46; Koniaris et al., supra note 13, at 1412-
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als on lethal injection and subsequently invited these authors to
contribute an additional commentary.
C. "Lethal Injection for Execution: Chemical Asphyxiation?"
in PoS Medicine 2007
Based upon our group's initial report into the lethal injection
process, we hypothesized that current characterization of the
pathophysiology of the lethal injection process was inaccurate.
Specifically, we noted evidence that even if proper administration
were achieved, errors in the lethal injection protocol drug design
might result in inadequate anesthesia and severe pain during the
process. We sought to evaluate the three-drug protocol for its pur-
ported efficacy in producing a rapid death with minimal likelihood
of pain and suffering. Our examination concentrated upon lethal
injection practice in both North Carolina and California where the
most data were available. In 2007, the results were published in
the world's fifth-most-cited general medical journal, Public Library
of Science (PloS) Medicine.27
We first examined the expert witness testimony that the 2 to 5
grams of thiopental used in execution itself might be lethal, that it
reliably induces rapid respiratory arrest, and that properly adminis-
tered, it should ensure sufficient anesthesia for the duration of the
lethal injection protocol.28 Clinical use of injectable anesthetics is
typically based upon body weight, not mass quantities as practiced
in lethal injection. We calculated actual thiopental doses given to
inmates in North Carolina using body weights recorded on autopsy
reports. In the forty reports available to us, the median calculated
dose of thiopental was 20.3 milligrams (mg) per kilogram (kg) of
body weight, ranging from a low of 11.2 mg/kg to a high of 44 mg/
kg.29 Assuming that inmates in all jurisdictions weigh approxi-
27. Teresa A. Zimmers et al., Lethal Injection for Execution: Chemical Asphyxia-
tion?, 4 PLoS MED. 0646-53 (2007).
28. See Declaration of Dr. Mark Heath 12-42, Beardlee v. Woodford, No. C 04-
5381 IF, 2005 WL 40073 (N.D. Cal. Jan.7, 2005); Affidavit of Mark Dershwitz, M.D.
9 9-15, Perkins v. Beck. No. 5:04-CT-643-BO, 2004 WL 5003233 (N.D. Cal. Sept. 27,
2004).
29. In North Carolina's first protocol, inmates were given 3 grams of thiopental,
regardless of body weight. In the second version of the protocol, half of the thiopental
was given after injection of the other two drugs, when the inmate would be theoreti-
cally dead. Thus, the actual amount of thiopental administered was 1.5 grams. In its
current protocol, North Carolina administers 3 grams of thiopental, regardless of
body weight. Recognizing that patient response to drugs is partially dependent upon
the patient's size, anesthesiologists administer drugs based upon body weight. See
Zimmers et al., supra note 27. According to the manufacturer, the recommended
926 [Vol. XXXV
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mately the same, we calculated that the equivalent dose range in
jurisdictions using 2 grams thiopental would be 6.6 to 30 mg/kg,
and in California using 5 grams would be 17 to 75 mg/kg. The man-
ufacturer recommends a starting dose of 3 to 6.6 mg/kg thiopental
for induction of anesthesia. 30 Thus the dose of thiopental used in
lethal injections overlaps the clinical range-clearly a dose not de-
signed to be fatal.
The most compelling data that thiopental is not sufficient to
cause death was found in execution logs from California. These
comprehensive logs which detail drug injection times, heart and
respiration rates, as well as time of cessation of heart beat and res-
piration and flat-lining of the electrocardiogram showed that in-
mates continued to breathe for 1 to 9 minutes after 5 grams
thiopental, indicating that thiopental does not reliably induce re-
spiratory arrest.31 The failure of thiopental to cause rapid, predict-
able death even in gravely ill patients has also been noted by
physicians participating in assisted suicides and euthanasia in the
Netherlands. In its report, the Netherlands Euthanasics Task
Force, concluded "it is not possible to administer so much of [thio-
pental] that a lethal effect is guaranteed. '' 32 Furthermore, it is
likely that condemned inmates, many of whom were chronic drug
and alcohol abusers and who are likely agitated and fearful at exe-
cution, would be more resistant to the effects of thiopental than
typical surgical patients, much less the terminally ill patients in the
Netherlands. Finally, typical clinical veterinary guidelines for large
animals such as dogs, sheep, and swine, specify single intravenous
injection of 18 to 22 mg/kg thiopental for non-painful procedures
lasting only 10 to 15 minutes.33 Importantly, swine are considered
an excellent model of human cardiopulmonary and cardiovascular
physiology and are of comparable body and brain size and cerebral
starting amount of thiopental when used for induction of anesthesia prior to the ad-
ministration of other, longer-acting agents, is 3 to 6.6 milligrams of thiopental per
kilogram of total body weight. See ABBOTT LABORATORIES, PENTOTHAL FOR INJEC-
TION, USP (THIOPENTAL SODIUM) 3-4 (1993), available at http://www.rxlist.com/cgi/
generic/thiopental.htm.
30. See ABBOTT LABORATORIES, supra note 29.
31. See Zimmers et al., supra note 27.
32. ROYAL DUTCH Soc'Y FOR THE ADVANCEMENT OF PHARMACY, THE HAGUE,
ADMINISTRATION AND COMPOUNDING OF EUTHANASIC AGENTS § 2.2.1 (1994).
33. See DENNIS F. KOHN ET AL., ANESTHESIA AND ANALGESIA IN LABORATORY
ANIMALS 426 (1997); DONALD C. PLUMB, VETERINARY DRUG HANDBOOK (5th ed.
2005).
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blood flow. 34 Given the absence of comparable patient data from
which to draw comparisons, it is prudent to conclude that when
doses in lethal injection are less than or equal to clinical veterinary
doses, adequate depth and duration of anesthesia cannot be as-
sured for the duration of the execution.
We next examined the mechanism by which death was effected
in the lethal injection process. The conventional wisdom and ex-
pert witness testimony typically agree that the mechanism of death
is or involves cardiac arrest from potassium chloride. When pa-
tients have been accidentally injected with concentrated potassium
chloride, they experience near instantaneous cardiac arrest and
death. In contrast, California data showed that many inmates
failed to undergo cardiac arrest for up to eight minutes after injec-
tion of potassium chloride, and that several inmates required multi-
ple injections of the drug.36 Furthermore, data from North
Carolina, which has used three versions of lethal injection, showed
that times to death were not statistically different in executions us-
ing potassium chloride versus those that did not.37 If potassium
were the agent of death, a shorter time to death should have been
noted in executions with potassium chloride. Thus, the available
evidence indicates that potassium chloride is not reliably the agent
of death in lethal injection.
Finally we inquired, "What is the mechanism of death if neither
thiopental nor potassium chloride acts in the manner postulated by
the expert witnesses?" We calculated that the dose of
pancuronium bromide in lethal injection is some 3 to 11 times the
dose used for intubation and would be predicted to induce rapidly
a paralysis lasting many hours.3 Thus in cases where thiopental
and potassium chloride are insufficient to cause death, death is
likely effected by paralysis and asphyxiation. Notably, in cases
where catheter misplacement causes administration of the drugs
under the skin or into the muscle rather than into the vein,
pancuronium bromide asphyxiation is almost certainly the sole
34. See James P. Hannon et al., Normal Physiological Values for Conscious Pigs
Used in Biomedical Research, 40 LABORATORY ANIMAL Sci. 293, 293-98 (1990).
35. See Angela R. Wetherton et al., Fatal Intravenous Injection of Potassium in
Hospitalized Patients, 24 AM. J. FORENSIC MED. PATHOLOGY 128, 128-31 (2003).
36. See Zimmers et al., supra note 27.
37. See id.
38. See Teva Pharmaceuticals, Pancuronium Bromide Injection Prescribing Infor-
mation, http://www.tevausa.com/assets/base/products/pi/Pancuronium%20PI%205-
2005.pdf (last visited April 17, 2008).
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mechanism of death as neither thiopental nor potassium chloride
would reach their target organs and have the desired effect.
The evidence presented in this report indicate that the assump-
tions underlying the lethal injection protocol that have been propa-
gated in the non-scientific literature and in the courtroom are not
supported by the literature, clinical veterinary practice, or the ob-
jective data collected in lethal injections in several states. This
finding should give pause to those on both sides of the lethal injec-
tion debate and should provoke a careful examination of proposals
to alter the lethal injection protocol by changing doses or eliminat-
ing drugs. If jurisdictions were to move to a thiopental-only proto-
col, for example, inmates might experience prolonged sleep, but.
eventually awaken as has been observed in primates and in physi-'
cian-assisted suicides in the Netherlands.
Ill. CONCLUSION
Until 2005, most of the scientific debate on lethal injection took,
place in often sealed testimony by expert witnesses testifying on
behalf of adversarial sides in litigation. The nature of the legal sys-
tem does not permit open, objective scientific inquiry and debate in
the manner that is provided by peer-review and publication. Our
studies presented here and published in the Lancet in 2005 and
PLoS Medicine in 2007 provide strong evidence that the lethal in-
jection protocol provides a substantial risk of inadequate anesthe-
sia both due to failures of process, as well as problems in the
protocol design itself. These studies should be considered by per-
sons on both sides of the lethal injection question, to inform the
debate, and to provide quantitative information upon which to
base decisions. Moreover, all should take note of the paucity of
information which is available and determine just what level of un-
certainty and risk is acceptable in this age of modern medicine and
high technology.
9292008]
sc a
AS
